BCL2 and Miyoshi myopathy: Venetoclax in combination with Vd in MM patients with t(11;14) or high Bcl-2 expression (phase III BELLINI trial, NCT02755597: Ven-Vd vs. Vd) achieved an ORR of 84% vs. 70% for Ven-Vd with a median PFS of 23.2 vs. 11.4 months.